Adjustment in the clinical practice of treat-to-target guidelines for rheumatoid arthritis: Results of the ToARCan study

被引:1
|
作者
Naranjo, Antonio [1 ,2 ]
Caceres, Laura [1 ,2 ]
Hernandez-Beriain, Jose Angel [3 ,5 ]
Francisco, Felix [1 ,2 ]
Ojeda, Soledad [1 ,2 ]
Talaverano, Sigrid
Novoa-Medina, Javier [5 ]
Adan Martin, Jose [4 ]
Delgado, Esmeralda
Trujillo, Elisa
Alvarez, Ftima
Magdalena, Laura
Rodriguez-Lozano, Carlos [1 ,2 ,6 ]
机构
[1] Hosp Univ Gran Canaria Dr Negrin, Serv Reumatol, Gran Canaria, Spain
[2] Univ Las Palmas Gran Canaria, Gran Canaria, Spain
[3] Complejo Hosp Univ Materno Insular Gran Canaria, Serv Reumatol, Gran Canaria, Spain
[4] Hosp Dr Molina Orosa, Serv Reumatol, Molina Orosa, Lanzarote, Spain
[5] Hosp Univ Canarias, Serv Reumatol, Tenerife, Spain
[6] Hosp Univ Nuestra Senora Candelaria, Serv Reumatol, Tenerife, Spain
来源
REUMATOLOGIA CLINICA | 2016年 / 12卷 / 01期
关键词
Rheumatoid arthritis; Treat-to-target; Health care quality; Adherence; DAS28; quality indicators;
D O I
10.1016/j.reuma.2015.03.003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective:To analyze compliance with t2t clinical practice guidelines. Methods:Cross-sectional observational study in consecutive patients with rheumatoid arthritis (RA) in 5 hospitals in the Canary Islands. Patients filled out activity scales, HAQ and answered the question of whether the doctor had explained the treatment target. The rheumatologist also collected: visits in the past year, use of activity indices and HAQ, DAS28 of current visit and date of the next visit. The percentage of compliance to indicators based on the t2t recommendations (R) 1, 3, 5-7 and 10 was analyzed. Results:A total of 343 patients were recruited, 77% female, mean age 57, RA duration of 10 years. Median visits in the last year were 3 and mean time between last and current visit was 5.6 months. A total of 93% of the patients were treated with DMARDs and 44% were in remission by DAS (R1). In the previous visit, documented joint count was present in 85%, a HAQ in 19%, patient VAS in 41%, and a DAS28 in 35% of the patients (R6). The next visit was scheduled at an average of 4.3 months (R5). In 64% of patients with DAS28> 3.2 a visit between one and 3 months was scheduled (R5). A total of 96% of patients said they had been informed of the treatment target (R10). Variability between centers existed but was moderate. The only factor determining the performance of a DAS28 in the last visit was the patient's center of origin. Conclusion:The Canary Island centers studied achieved high levels of remission and low activity in their patients. The performance of composite indices and follow-up frequency recommended by the t2t are met, although there is room for improvement. (C) 2014 Elsevier Espana, S.L.U.y Sociedad Espanola de Reumatologia y Colegio Mexicano de Reumatologia. All rights reserved.
引用
收藏
页码:34 / 38
页数:5
相关论文
共 50 条
  • [31] Long-term outcomes of treat-to-target strategy in established rheumatoid arthritis: a daily practice prospective cohort study
    Bueno de Andrade, Nicole Pamplona
    da Silva Chakr, Rafael Mendonca
    Xavier, Ricardo Machado
    Viecceli, Daniela
    Bilycz Correa, Ricardo Henrique
    de Oliveira Filho, Cilomar Martins
    Brenol, Claiton Viegas
    RHEUMATOLOGY INTERNATIONAL, 2017, 37 (06) : 993 - 997
  • [32] Differences in Treat-to-Target in Patients with Rheumatoid Arthritis versus Hypertension and Diabetes Consequences for Clinical Care
    Castrejon, Isabel
    Pincus, Theodore
    BULLETIN OF THE HOSPITAL FOR JOINT DISEASES, 2011, 69 (02): : 104 - 110
  • [33] Long-term outcomes of treat-to-target strategy in established rheumatoid arthritis: a daily practice prospective cohort study
    Nicole Pamplona Bueno de Andrade
    Rafael Mendonça da Silva Chakr
    Ricardo Machado Xavier
    Daniela Viecceli
    Ricardo Henrique Bilycz Correa
    Cilomar Martins de Oliveira Filho
    Claiton Viegas Brenol
    Rheumatology International, 2017, 37 : 993 - 997
  • [34] Reduced Subclinical and Clinical Atherosclerosis by a Treat-to-Target Intervention of Cardiovascular Risk Factors in Rheumatoid Arthritis: Results of the francis, a Randomized Clinical Trial
    Burggraaf, Benjamin
    van Breukelen-van der Stoep, Deborah F.
    de Vries, Marijke A.
    Klop, Boudewijn
    Liem, Anho H.
    van de Geijn, Gert-Jan M.
    van der Meulen, Noelle
    Birnie, Erwin
    van der Zwan, Ellen
    Van Zeben, Jende
    Cabezas, Castro Manuel
    CIRCULATION, 2018, 138
  • [35] Treat-to-target and shared decision making in rheumatoid arthritis treatment: Is it feasible?
    Falzer, Paul R.
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2019, 22 (09) : 1706 - 1713
  • [36] DOES POLYPHARMACY IN RHEUMATOID ARTHRITIS PATIENTS AFFECT THE TREAT-TO-TARGET STRATEGY?
    Jaramillo Gallego, John Fredy
    Rosa, Javier
    Scolnik, Marina
    Tobar Jaramillo, Maya Alejandra
    Garcia, Maria Victoria
    Ferreyra, Leandro
    Soriano, E. R.
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2020, 26 : 13 - 14
  • [37] Rheumatoid Arthritis: How well does the Treat-to-Target Strategy work?
    Lorenz, Judith
    AKTUELLE RHEUMATOLOGIE, 2020, 45 (04) : 266 - 266
  • [38] Adherence to a Treat-to-Target (T2T) Strategy in Early Rheumatoid Arthritis. Is It Feasible in Daily Clinical Practice?
    Waimann, Christian A.
    Citera, Gustavo
    Dal Pra, Fernando
    Celeste Orozco, Maria
    Ceccatto, Federico
    Paira, Sergio
    Gauna, M.
    Secco, Anastasia
    Mamani, M.
    Marino, Lucila
    Caeiro, Francisco
    Alvarez, A. C.
    Haye Salinas, Maria
    Encinas, L.
    Rosa, Javier
    Scaglioni, Valeria
    Soriano, Enrique R.
    Marcos, Josefina
    Garcia, Mercedes
    Salas, A.
    Martinez, Alejandro
    Chaparro del Moral, Rafael
    Luis Rillo, Oscar
    Berman, Horacio
    Berman, Alberto
    Colombres, Francisco
    Veloso, Edson
    Juarez, Ricardo V.
    Elena Crespo, Maria
    Quinteros, Ana
    Leal, M.
    Salvatierra, Gabriela
    Ledesma, C.
    Sacnun, Monica P.
    Quintana, R.
    Abdala, Marcelo
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S1037 - S1037
  • [39] Overview and analysis of treat-to-target trials in rheumatoid arthritis reporting on remission
    Jurgens, M. S.
    Welsing, P. M. J.
    Jacobs, J. W. G.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2012, 30 (04) : S56 - S63
  • [40] Analysis of Rheumatoid Arthritis Patients That Did Not Achieve the Treatment Goal By the Treat-to-Target Strategy in Daily Practice
    Yamazaki, Hideshi
    Takanashi, Tetsuo
    ARTHRITIS & RHEUMATOLOGY, 2017, 69